Navigation Links
Lipitor Reduces Risk of Major Cardiovascular Events

Lipitor could help in controlling heart disease, and other major cardiovascular risk factors, which are commonly called as ‘Metabolic Syndrome’. //

According to the new study that has been published today on the Lancet's Web site, larger doses of Lipitor, the cholesterol-lowering drug of Pfizer further might lower the so-called ‘bad’ cholesterol and prevent serious heart or circulatory conditions in certain patients.

The researchers in the study have shown that patients with coronary heart disease and metabolic syndrome who took 80 milligrams of Lipitor a day had lower low-density lipoprotein, or ‘bad’ cholesterol, than patients on 10 milligrams a day. They explained in their findings that patients on a higher-dose had a 9.5% risk of death from coronary heart disease, heart attack, cardiac arrest or stroke, when compared to 13% in respect with others.

Prakash Deedwania, a professor of cardiology at the University of California School of Medicine in San Francisco and lead author of the study said, “This clearly suggests that the higher dose of Lipitor provides substantially greater benefits”.

It is reported that Pfizer, had funded the study, as it is seeking to expand the market for Lipitor. The drug is already the world's top-selling drug, which had generated sales of $12.2 billion in 2005 for Pfizer, but now faces stiff competition from generics, like Zocor from Merck & Co, which is slated as the 6th best-selling treatment in the world that had generated a revenue of around $4.4 billion last year, and AstraZeneca's Crestor, which had sales of $387 million in the first quarter of 2006.

The researchers explained that they had conducted the study by enrolling 5,584 patients with coronary heart disease and metabolic syndrome at 256 centers around 14 countries and monitored them for about five years. They explained that high levels of low-density lipoprotein are a risk factor for heart and circulatory diseases. Deedwania explained that the diagnosis of metabolic syndrome is usually made in patients with three cardiovascular risk factors, like insulin resistance, obesity, and large waistline, high blood pressure and lipoprotein imbalances. He further stressed that these days the condition is “at epidemic proportions throughout the world” and is directly related to obesity of the population.

Andre Scheen, a Belgian researcher, writing in a comment that accompanied the study, said, “The TNT findings suggest that the presence of metabolic syndrome might help to select patients who will best benefit from aggressive lipid-lowering therapy.

According to the World Health Organization, diseases due to cardiovascular condition like heart attacks and strokes are the leading cause of death and kill about 17 million people a year.



Source-Medinia
VIK
'"/>




Related medicine news :

1. Drug Reduces Risk of Clogged Arteries, Veins
2. Sunshine Reduces MS Risk
3. Estrogen in Food Reduces Cancer Risk
4. Dental Procedure Reduces Preterm Births
5. Vaccine Reduces antibiotic-resistant infections in Children
6. Eating Fiber Reduces The Risk Of Heart Disease
7. Higher Statin Dose Safely Reduces Stroke and Cardiac Arrest
8. Anti-tobacco Advertising Can Reduces smoking Among Teens
9. Eating Fish Reduces Heart Disease
10. Co-trimoxazole Use Reduces Childhood AIDS –Related Death
11. NSAIDS, Reduces The Risk Of Oral Cancer But Causes Heart Attacks
Post Your Comments:
*Name:
*Comment:
*Email:


(Date:4/21/2017)... ... April 21, 2017 , ... Brady (NYSE:BRC), a ... B-595 and B-7569 vinyl label materials received certification for the ... are tested to remain intact and legible, for use on chemical drums shipped by ...
(Date:4/21/2017)... ... ... The Patient Advocacy Community of The Beryl Institute presented Eve DeVaro, Director, Patient ... Award in recognition of her extraordinary contributions to the field of patient advocacy ... Institute’s annual Patient Experience Conference on March 20 in Denver, Colorado. ...
(Date:4/21/2017)... , ... April 21, 2017 , ... ... weeklong campaign, AWARE: A Week of Addiction and Recovery Education, from April 24 ... treating and preventing substance use disorders. , The mission of AWARE is ...
(Date:4/21/2017)... ... April 21, 2017 , ... Metrasens is honoured ... Trade, the UK’s most prestigious award for business success. The company has ... revenues and has grown by a total of 400% over the last six ...
(Date:4/21/2017)... ... April 21, 2017 , ... Westside Dental Associates ... dental care since 1985. After thirty-two years, Dr. Latner has become one of the ... my numerous clients over the years with all their dental needs,” said Dr. Latner, ...
Breaking Medicine News(10 mins):
(Date:4/20/2017)... 2017  AbbVie (NYSE: ABBV), a global biopharmaceutical ... chronic hepatitis C virus (HCV) infected patients with ... compensated cirrhosis (Child-Pugh A) achieved sustained virologic response ... its investigational, pan-genotypic regimen of glecaprevir/pibrentasvir (G/P). These ... 12 weeks of G/P treatment without ribavirin. Patients ...
(Date:4/20/2017)... 2017 Research and Markets has announced ... Services Market Analysis By Service (Manufacturing, Research), By Country, (Brazil, ... 2025" report to their offering. ... The Latin American pharmaceutical contract manufacturing services ... Low drug registration cost in Latin American countries ...
(Date:4/19/2017)... Calif. , April 19, 2017  IRIDEX Corporation ... will release financial results for the first quarter 2017 ... 2017.  The Company,s management team will host a corresponding ... p.m. ET. Investors interested in listening to ... 707-0665 for domestic callers or (703) 326-3030 for international ...
Breaking Medicine Technology: